Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Feb 15, 2021; 13(2): 119-130
Published online Feb 15, 2021. doi: 10.4251/wjgo.v13.i2.119
Published online Feb 15, 2021. doi: 10.4251/wjgo.v13.i2.119
Table 1 Patient characteristics
| Characteristic | Standard therapy, n = 72, (%) | TNT, n = 89, (%) | P value | |
| Age in year | < 65 | 29 (40) | 66 (74) | < 0.001 |
| ≥ 65 | 43 (60) | 23 (26) | ||
| Range | 40-84 | 33-79 | ||
| mean [SD] | 65.4 [10.5] | 57.5 [10.1] | < 0.001 | |
| Sex | M | 45 (63) | 54 (61) | 0.813 |
| F | 27 (38) | 35 (39) | ||
| PS WHO | 0 | 48 (67) | 67 (75) | 0.229 |
| 1 | 24 (33) | 22 (25) | ||
| High-risk factors for failure | cT4 | 15 (21) | 33 (37) | 0.025 |
| cN2 | 49 (68) | 62 (70) | 0.827 | |
| MRF+ | 39 (54) | 66 (74) | 0.008 | |
| EMVI+ | 27 (38) | 65 (73) | < 0.001 | |
| Lateral node | 15 (21) | 8 (9) | 0.033 | |
| cTN | T2N2 | 1 (1) | 1 (1) | 0.1381 |
| T3N0 | 1 (1) | 0 (0) | ||
| T3N1 | 21 (29) | 20 (22) | ||
| T3N2 | 34 (47) | 35 (39) | ||
| T4N1 | 1 (1) | 7 (8) | ||
| T4N2 | 14 (19) | 26 (29) | ||
| Distance from anal verge in cm | ≤ 5 | 27 (38) | 29 (33) | 0.370 |
| 5.1-10 | 37 (51) | 43 (48) | ||
| ≥ 10.1 | 8 (11) | 17 (19) | ||
- Citation: Tuta M, Boc N, Brecelj E, Peternel M, Velenik V. Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure. World J Gastrointest Oncol 2021; 13(2): 119-130
- URL: https://www.wjgnet.com/1948-5204/full/v13/i2/119.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i2.119